WO2023286611A1 - 断片化細胞外マトリックス成分の製造方法 - Google Patents
断片化細胞外マトリックス成分の製造方法 Download PDFInfo
- Publication number
- WO2023286611A1 WO2023286611A1 PCT/JP2022/026062 JP2022026062W WO2023286611A1 WO 2023286611 A1 WO2023286611 A1 WO 2023286611A1 JP 2022026062 W JP2022026062 W JP 2022026062W WO 2023286611 A1 WO2023286611 A1 WO 2023286611A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extracellular matrix
- fragmented
- collagen
- solution
- component
- Prior art date
Links
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 238
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 235
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 235
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 189
- 239000007788 liquid Substances 0.000 claims abstract description 93
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 41
- 239000002904 solvent Substances 0.000 claims abstract description 30
- 239000003495 polar organic solvent Substances 0.000 claims abstract description 29
- 238000004108 freeze drying Methods 0.000 claims abstract description 22
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims description 314
- 108010035532 Collagen Proteins 0.000 claims description 314
- 229920001436 collagen Polymers 0.000 claims description 314
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 167
- 210000004027 cell Anatomy 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 238000013467 fragmentation Methods 0.000 claims description 38
- 238000006062 fragmentation reaction Methods 0.000 claims description 38
- 238000005259 measurement Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 20
- 239000012736 aqueous medium Substances 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002525 ultrasonication Methods 0.000 claims description 6
- YHPJVEVBHRHVGO-UHFFFAOYSA-N 1-anilinonaphthalene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2C=CC=CC2=C1NC1=CC=CC=C1 YHPJVEVBHRHVGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 125
- 230000000052 comparative effect Effects 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 238000001879 gelation Methods 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 229910021642 ultra pure water Inorganic materials 0.000 description 20
- 239000012498 ultrapure water Substances 0.000 description 20
- 238000001142 circular dichroism spectrum Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 238000001035 drying Methods 0.000 description 18
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 9
- 108010022452 Collagen Type I Proteins 0.000 description 9
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 8
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 8
- 206010061592 cardiac fibrillation Diseases 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000002600 fibrillogenic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- IRKGXNAZPUOEMW-UHFFFAOYSA-L magnesium;8-anilinonaphthalene-1-sulfonate Chemical compound [Mg+2].C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1.C=12C(S(=O)(=O)[O-])=CC=CC2=CC=CC=1NC1=CC=CC=C1 IRKGXNAZPUOEMW-UHFFFAOYSA-L 0.000 description 6
- 238000000879 optical micrograph Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000012571 GlutaMAX medium Substances 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 102000000641 Non-Fibrillar Collagens Human genes 0.000 description 1
- 108010002466 Non-Fibrillar Collagens Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 229910000487 osmium oxide Inorganic materials 0.000 description 1
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- the present invention relates to a method for producing fragmented extracellular matrix components.
- the present invention also relates to fragmented extracellular matrix components and methods of producing cell constructs using the same.
- a technique for producing a cell structure that mimics a living tissue in vitro.
- a cell culture method for obtaining a cell structure culturing cells in the presence of an extracellular matrix component such as collagen is generally performed.
- Patent Document 1 discloses a three-dimensional tissue forming agent containing fragmented collagen, wherein the average length of the fragmented collagen is 100 nm to 200 ⁇ m and the average diameter of the fragmented collagen is 50 nm to 30 ⁇ m. , discloses a three-dimensional tissue forming agent.
- fragmented extracellular matrix components were obtained by dispersing extracellular matrix components such as freeze-dried collagen in a buffer solution and then homogenizing with a homogenizer or the like.
- extracellular matrix component such as collagen partially dissolves in the buffer solution during preparation just before use, resulting in a decrease in yield.
- the present invention provides a method for producing a fragmented extracellular matrix component that can obtain a fragmented extracellular matrix component that is excellent in redispersibility even when stored in a dry state and that yields a higher yield than conventional methods. With the goal.
- Another object of the present invention is to provide a fragmented extracellular matrix component that exhibits excellent redispersibility even when stored in a dry state, and to provide a method for producing a cell structure using the fragmented extracellular matrix component.
- a method for producing a fragmented extracellular matrix component comprising: a step of neutralizing the solution in which the extracellular matrix components are dissolved; After the neutralization step, the solvent is removed by freeze-drying to obtain a mass containing extracellular matrix components; dispersing the lumps in a solution containing a polar organic solvent to fragment the extracellular matrix components in the solution to obtain a liquid containing the fragmented extracellular matrix components; and removing a liquid component from the liquid containing the fragmented extracellular matrix component.
- a section sample is prepared, and a rectangular region with a long side of 1820 ⁇ m and a short side of 1365 ⁇ m is observed with a microscope.
- the present invention it is possible to obtain a fragmented extracellular matrix component with excellent redispersibility even when stored in a dry state, and to provide a method for producing a fragmented extracellular matrix component with an improved yield compared to conventional methods. can do.
- the present invention also provides a fragmented extracellular matrix component that exhibits excellent redispersibility even when stored in a dry state, and a method for producing a cell structure using the fragmented extracellular matrix component. can be done.
- FIG. 3 is an optical micrograph of fragmented collagen resuspended in ultrapure water.
- FIG. 1(A) shows the fragmented collagen obtained in Production Example 1.
- FIG. 1(B) shows the fragmented collagen obtained in Comparative Production Example 1.
- FIG. 1 is a CD spectrum of fragmented collagen obtained in Production Example 1.
- FIG. Fig. 3 is a photograph of fragmented collagen stained with hematoxylin and eosin (HE).
- 3(A) and (C) are photographs of the fragmented collagen obtained in Comparative Production Example 1 taken at magnifications of 10 and 40, respectively.
- 3(B) and (D) are photographs of the fragmented collagen obtained in Production Example 1 taken at magnifications of 10 and 40, respectively.
- FIG. 3 is an optical micrograph of fragmented collagen resuspended in ultrapure water.
- FIG. 5(A) shows the fragmented collagen obtained in Production Example 1.
- FIG. 5(B) shows the fragmented collagen obtained in Production Example 2-3.
- FIG. 5(C) shows the fragmented collagen obtained in Production Example 2-1.
- FIG. 3 is a CD spectrum of fragmented collagen obtained in Production Example 2-3.
- FIG. Fig. 3 is an optical micrograph of fragmented collagen resuspended in ultrapure water.
- FIG. 7(A) shows the fragmented collagen obtained in Production Example 3-1.
- FIG. 7(B) shows the fragmented collagen obtained in Production Example 3-2.
- FIG. 7(C) shows the fragmented collagen obtained in Production Example 3-3.
- FIGS. 8(A) and (C) are photographs of collagen after neutralization and gelation, taken at magnifications of 500 and 2000, respectively.
- FIGS. 8(B) and (D) are photographs of neutralized collagen taken at magnifications of 500 and 2000, respectively. It is a photograph of a gelled collagen solution.
- 10A and 10B are photographs of cell structures stained with hematoxylin and eosin (HE) (FIGS. 10A and 10C) or immunostained with CD31 (FIG. 10B).
- 10(A) and (B) are cell structures produced using the fragmented collagen obtained in Production Example 1.
- FIG. 10(C) shows a cell structure produced using the fragmented collagen obtained in Comparative Production Example 1.
- FIG. It is a photograph of fragmented collagen dispersed by a pipetting operation. 1 is a phase-contrast micrograph of redispersed fragmented collagen.
- Fig. 3 shows CD spectra of gelatin, raw material collagen (Native Collagen), and fragmented collagen obtained by the method of Production Example 5-4.
- Fig. 10 is a photograph showing a section image of a cell structure prepared using fragmented collagen, stained with hematoxylin and eosin (HE) and CD31.
- 1 is a phase-contrast photomicrograph showing evaluation results of the influence of the presence or absence of ultrasonic defibration on fragmented collagen.
- Fig. 10 is a photograph showing a section image of a cell structure showing the evaluation result of the influence of the presence or absence of ultrasonic fibrillation on fragmented collagen.
- 1 is a micrograph showing observation results of fragmented collagen produced using acetone, acetonitrile, and diethyl ether as polar organic solvents. It is a graph which shows a hydrophobicity evaluation result.
- the method for producing a fragmented extracellular matrix component includes a step of neutralizing a solution in which the extracellular matrix component is dissolved (neutralization step), and after the neutralization step, the solvent is removed by freeze-drying. to obtain a mass containing extracellular matrix components (solvent removal step); dispersing the mass in a solution containing a polar organic solvent to fragment the extracellular matrix components in the solution; It comprises a step of obtaining a liquid containing the component (fragmentation step) and a step of removing the liquid component from the liquid containing the fragmented extracellular matrix component (drying step).
- a step of gelling the neutralized solution after the neutralization step and before the solvent removal step may be further provided.
- the liquid component in the liquid obtained in the fragmentation step is diluted with water. It may further comprise a step of substituting (substitution step).
- the liquid containing the fragmented extracellular matrix component is subjected to ultrasonic crushing treatment.
- a step of performing (ultrasonic crushing step) may be further provided.
- the method for producing a fragmented extracellular matrix component according to the present embodiment may further include a step of dispersing the solid matter obtained in the drying step in an aqueous medium (washing step) in addition to the steps described above.
- the neutralization step is a step of neutralizing the solution in which the extracellular matrix components are dissolved. Since the structure of the extracellular matrix is changed by neutralization, it is possible to obtain a fragmented extracellular matrix component that is excellent in redispersibility even when stored in a dry state by carrying out in conjunction with the subsequent steps. become.
- extracellular matrix component refers to an aggregate of extracellular matrix molecules formed by multiple extracellular matrix molecules (also simply referred to as "extracellular matrix”).
- Extracellular matrix means a substance that exists outside cells in an organism. Any substance can be used as the extracellular matrix as long as it does not adversely affect the growth of cells and the formation of cell aggregates.
- Specific examples of extracellular matrices include, but are not limited to, collagen, elastin, proteoglycan, fibronectin, hyaluronic acid, laminin, vitronectin, tenascin, entactin and fibrillin.
- the extracellular matrix component may contain one type of extracellular matrix alone, or may contain two or more types in combination.
- the extracellular matrix may be a modification or variant of the above-mentioned extracellular matrix, or a polypeptide such as a chemically synthesized peptide, as long as it does not adversely affect cell growth and cell aggregate formation.
- the extracellular matrix may have repeating sequences represented by Gly-XY, characteristic of collagen.
- Gly represents a glycine residue
- X and Y each independently represent any amino acid residue.
- a plurality of Gly-XY may be the same or different.
- the proportion of the sequence represented by Gly-XY in the total amino acid sequence may be 80% or more, preferably 95% or more.
- the extracellular matrix may be a polypeptide having an RGD sequence.
- the RGD sequence refers to a sequence represented by Arg-Gly-Asp (arginine residue-glycine residue-aspartic acid residue). Having an RGD sequence further promotes cell adhesion, making it more suitable as a scaffold material for cell culture, for example.
- Extracellular matrices containing a sequence represented by Gly-XY and an RGD sequence include collagen, fibronectin, vitronectin, laminin, cadherin and the like.
- Collagen includes, for example, fibrous collagen and non-fibrous collagen.
- Fibrous collagen means collagen that is the main component of collagen fibers, and specific examples thereof include type I collagen, type II collagen, and type III collagen.
- Non-fibrillar collagens include, for example, type IV collagen.
- Proteoglycans include, but are not limited to, chondroitin sulfate proteoglycans, heparan sulfate proteoglycans, keratan sulfate proteoglycans, and dermatan sulfate proteoglycans.
- the extracellular matrix component may contain at least one selected from the group consisting of collagen, laminin and fibronectin, and preferably contains collagen.
- the collagen is preferably fibrillar collagen, more preferably type I collagen.
- Commercially available collagen may be used as the fibrous collagen, and a specific example thereof is porcine skin-derived type I collagen manufactured by Nippon Ham Co., Ltd.
- the extracellular matrix component may be an animal-derived extracellular matrix component.
- animal species from which extracellular matrix components are derived include, but are not limited to, humans, pigs, and bovines.
- As the extracellular matrix component a component derived from one kind of animal may be used, or a combination of components derived from a plurality of kinds of animals may be used.
- the solvent for the solution in which the extracellular matrix components are dissolved is not particularly limited as long as it can dissolve the extracellular matrix components.
- Specific examples of solvents include water and buffers (eg, phosphate-buffered saline (PBS), Tris-HCl buffer (Tris-HCl)).
- the concentration of the extracellular matrix component in the solution in which the extracellular matrix component is dissolved is not particularly limited, but may be, for example, 1 mg/mL or more and 50 mg/mL or less.
- the neutralization step can be carried out, for example, by adding an alkaline solution to the solution in which the extracellular matrix components are dissolved.
- the alkaline solution is not particularly limited, for example, a solution obtained by dissolving an alkali metal hydroxide, an alkaline earth metal hydroxide, or the like in water can be preferably used. More specific examples of the alkaline solution include potassium hydroxide (KOH) aqueous solution, sodium hydroxide (NaOH) aqueous solution, and the like.
- the neutralization step can be performed, for example, by adding an acidic solution to the solution in which the extracellular matrix components are dissolved.
- the acidic solution is not particularly limited, and examples thereof include hydrochloric acid solution, sulfuric acid solution, acetic acid solution, carbonate solution and the like.
- the pH of the solution after neutralization may be, for example, within the range of 6 or more and 8 or less, preferably 6.5 or more and 7.5 or less, and 6.9 or more and 7.5. It is more preferably within the range of 1 or less, and further preferably within the range of 6.95 or more and 7.05 or less.
- the gelation step is the step of gelling the neutralized solution after the neutralization step and before the solvent removal step.
- the gelation step may be performed as necessary.
- the gelation step can be performed, for example, by heating the neutralized solution to gel it.
- the temperature and heating time during heating can be appropriately set according to the type, concentration, etc. of the extracellular matrix component. Three hours can be exemplified.
- the gelation step it is possible to confirm whether the solution is uniformly neutralized in the neutralization step by visually determining whether the formed gel is uniform.
- the mass containing extracellular matrix components obtained in the solvent removal step becomes a porous body, and fragmentation in the fragmentation step can be performed more efficiently.
- the solvent removal step is a step of removing the solvent by freeze-drying after the neutralization step (after the gelation step when the gelation step is included) to obtain a mass containing extracellular matrix components.
- the solution after neutralization or the freeze-drying treatment of the gel after gelation can be carried out according to a conventional method.
- the solvent removal step removes the solvent to obtain a mass (solid) containing extracellular matrix components.
- the removal of the solvent does not mean that no solvent is attached to the mass (solid) containing the extracellular matrix component. It means that the solvent is not attached to the extent possible.
- the fragmentation step is a step of dispersing the aggregates obtained in the solvent removal step in a solution containing a polar organic solvent, fragmenting the extracellular matrix components in the solution, and obtaining a liquid containing the fragmented extracellular matrix components.
- Fragmentation in a solution containing a polar organic solvent yields a fragmented extracellular matrix component that exhibits excellent redispersibility even when stored in a dry state, and suppresses the dissolution of the extracellular matrix component into the solution.
- the yield is further improved compared to the conventional method.
- the polar organic solvent is not particularly limited as long as it is an organic solvent having polarity, and examples thereof include alcohols such as methanol, ethanol, n-propanol and isopropanol, acetone, acetonitrile and diethyl ether.
- the concentration of the polar organic solvent in the solution containing the polar organic solvent is not particularly limited, it should be 20 v/v% or more and 100 v/v% or less from the viewpoint that the above effects can be exhibited more remarkably. is preferred.
- the concentration of the polar organic solvent in the solution containing the polar organic solvent may be, for example, 20 v/v% or more and 50 v/v% or less, may be 20 v/v% or more and 40 v/v% or less, and may be 20 v/v % or more and 30 v/v % or less.
- the concentration of the polar organic solvent in the solution containing the polar organic solvent is, for example, 50 v/v% or more and 100 v/v% or less, 50 v/v% or more and 90 v/v% or less, or 50 v/v% or more and 80 v/v% or less. 60 v/v% or more and 100 v/v% or less, 60 v/v% or more and 90 v/v% or less, or 60 v/v% or more and 80 v/v% or less.
- fragmentation means reducing aggregates of extracellular matrix molecules to a smaller size. Fragmentation may be performed under conditions that cleave bonds within extracellular matrix molecules, or under conditions that do not cleave bonds within extracellular matrix molecules. Extracellular matrices that have been fragmented by the application of physical force usually do not change their molecular structure (the molecular structure is maintained) unlike enzymatic treatment. Fragmented extracellular matrix components may contain defibrated extracellular matrix components (fibrillated extracellular matrix components), which are components obtained by defibrating the above-described extracellular matrix components by applying physical force. . Defibrillation is one mode of fragmentation, and is performed under conditions that do not break bonds within extracellular matrix molecules, for example.
- the fragmentation step includes dispersing the mass obtained in the solvent removal step in a solution containing a polar organic solvent, and extracting the extracellular matrix component in the solution. It may be configured as a step of defibrating to obtain a liquid containing fibrillated extracellular matrix components (fibrillation step).
- the method for fragmenting extracellular matrix components is not particularly limited, and may be fragmented by applying physical force.
- a homogenizer such as an ultrasonic homogenizer, a stirring homogenizer, and a high-pressure homogenizer may be used to fragment the extracellular matrix components by applying physical force. good. It is also possible to obtain millimeter-sized or nanometer-sized fragmented extracellular matrix components by adjusting the homogenization time, number of times, and the like.
- More specific conditions for fragmenting the extracellular matrix components include, for example, using a homogenizer (manufactured by AS ONE, VH-10) and treating at 20,000 rpm to 30,000 rpm for 3 to 10 minutes, or Conditions under which a corresponding physical force can be applied can be mentioned.
- the fragmented extracellular matrix component may at least partially contain a defibrated extracellular matrix component. Moreover, the fragmented extracellular matrix component may consist of only the defibrated extracellular matrix component. That is, the fragmented extracellular matrix component may be a defibrated extracellular matrix component.
- the defibrated extracellular matrix component preferably contains fibrillated collagen (fibrillated collagen).
- the defibrillated collagen preferably maintains the triple helical structure derived from collagen.
- the defibrated collagen may partially maintain the triple helical structure derived from collagen.
- the shape of the fragmented extracellular matrix component includes, for example, a fibrous shape.
- the fibrous shape means a shape composed of filamentous extracellular matrix components, or a shape composed of filamentous extracellular matrix components crosslinked between molecules. At least some of the fragmented extracellular matrix components may be fibrous.
- Fibrous extracellular matrix components include thin filaments (fibrils) formed by aggregation of a plurality of filamentous extracellular matrix molecules, filaments formed by further aggregation of fine fibrils, and these filaments. Including defibrated ones. The RGD sequence is preserved without disruption in fibrous extracellular matrix components.
- the average length of the fragmented extracellular matrix component may be 100 nm or more and 400 ⁇ m or less, and may be 100 nm or more and 200 ⁇ m or less. In one embodiment, the average length of the fragmented extracellular matrix component may be 5 ⁇ m or more and 400 ⁇ m or less, 10 ⁇ m or more and 400 ⁇ m or less, 22 ⁇ m or more and 400 ⁇ m or less, or 100 ⁇ m or more and 400 ⁇ m or less. good. In other embodiments, the average length of the fragmented extracellular matrix components may be 100 ⁇ m or less, 50 ⁇ m or less, 30 ⁇ m or less, 15 ⁇ m or less, 10 ⁇ m or less.
- the average diameter of the fragmented extracellular matrix components may be 10 nm or more and 10 ⁇ m or less, 20 nm or more and 8 ⁇ m or less, 30 nm or more and 6 ⁇ m or less, or 50 nm or more and 4 ⁇ m or less.
- the average length and average diameter of the fragmented extracellular matrix components can be determined by measuring individual fragmented extracellular matrix components with an optical microscope and analyzing the images.
- average length means the average length of the measured sample in the longitudinal direction
- average diameter means the average length of the measured sample in the direction orthogonal to the longitudinal direction. means.
- the liquid contains, in addition to the fragmented extracellular matrix component, a solution containing a polar organic solvent, or the like.
- the replacement step is a step of replacing the liquid component in the liquid obtained in the fragmentation step with water after the fragmentation step and before the drying step.
- the fragmented extracellular matrix component obtained through the drying process can be rapidly redispersed.
- Examples of water include tap water, distilled water, and ultrapure water.
- the method for replacing the liquid component in the liquid obtained in the fragmentation step with water is not particularly limited, and a normal method for solvent replacement can be used.
- a method of replacing with water the liquid obtained in the fragmentation step is centrifuged to precipitate the fragmented extracellular matrix components in the liquid, then the liquid component is removed, and then the fragmented extracellular matrix is removed.
- a method of adding water to the matrix component is included. Note that replacing the liquid component with water does not mean that all the liquid components present in the liquid are replaced with water, but means that the main solvent in the liquid is replaced with water. A small amount of liquid components other than water may remain.
- the liquid obtained through the replacement process contains water in addition to the fragmented extracellular matrix components.
- the ultrasonic crushing step is a step of subjecting the liquid obtained in the fragmentation step to ultrasonic crushing treatment.
- the ultrasonic crushing step may be performed as necessary. Through the ultrasonication process, it is possible to obtain a fragmented extracellular matrix component that is dispersed more uniformly and is less likely to aggregate when used for organization.
- Ultrasonic crushing treatment can crush the fragmented extracellular matrix components while cooling, and thus has the advantage that the possibility of thermal denaturation of the fragmented extracellular matrix components is low and large-scale equipment is not required.
- the ultrasonic crushing process can be performed using an ultrasonic crusher.
- an ultrasonic crusher for example, a fully automatic ultrasonic crusher such as BIORUPTORII manufactured by BM Kiki Co., Ltd. can be used.
- the ultrasonic crushing treatment may be carried out by repeatedly irradiating the liquid obtained in the fragmentation step with ultrasonic waves and cooling the liquid.
- the ultrasonic crushing treatment may be carried out, for example, by repeating ultrasonic irradiation for 10 to 30 seconds and cooling for 20 to 40 seconds at an ultrasonic frequency of 20 kHz 50 to 150 times.
- the fragmented extracellular matrix components may dissolve. Therefore, in order to obtain finely fragmented extracellular matrix components by ultrasonication, for example, the fragmented extracellular matrix components or their precursors are subjected to thermal cross-linking treatment to prevent dissolution during ultrasonication. I needed it.
- the fragmented extracellular matrix component may be denatured by the thermal cross-linking treatment, and the tissue obtained using the denatured fragmented extracellular matrix component may differ greatly from the living tissue. Fragmented extracellular matrix components obtained by fragmentation in a solution containing a polar organic solvent do not dissolve easily even when the liquid components are replaced with water.
- the resulting fragmented extracellular matrix components can be subjected to ultrasonic disruption without treatment that can denature the fragmented extracellular matrix components, thereby dispersing them more uniformly and improving their organization. Fragmented extracellular matrix components that are less likely to aggregate when used can be obtained.
- the drying step is a step of removing liquid components from the liquid containing the fragmented extracellular matrix components obtained in the fragmentation step.
- Removal of liquid components can be carried out, for example, by air drying, freeze drying, reduced pressure drying, reduced pressure freeze drying, and the like. Removal of liquid components may be performed by air-drying or freeze-drying processes. It is preferable to remove the liquid component by air-drying, because fragmented extracellular matrix components with excellent redispersibility can be easily obtained even when stored in a dry state.
- the drying process removes the liquid component to obtain a solid containing dried fractionated extracellular matrix components.
- the removal of the liquid component does not mean that no liquid component adheres to the solid material containing the dried fractionated extracellular matrix component, and the general drying method described above does not mean that no liquid component adheres to the solid material. , means that the liquid component is not adhered to the extent that common sense can be reached.
- the washing step is a step of dispersing the solid matter obtained in the drying step in an aqueous medium.
- the washing step may be performed as necessary.
- the washing step removes unnecessary components (for example, salts) from the solid containing the fragmented extracellular matrix components, thereby obtaining fragmented extracellular matrix components of higher purity.
- the aqueous medium used in the washing step is preferably capable of dispersing the fragmented extracellular matrix components and dissolving the unnecessary components described above.
- aqueous media include water, phosphate buffered saline (PBS), Tris buffer (Tris), and the like.
- a dried fragmented extracellular matrix component can be obtained at a higher yield than the conventional method.
- the resulting dried fragmented extracellular matrix components are excellent in redispersibility, and can be easily redispersed, for example, by adding an arbitrary solvent and performing a pipetting operation.
- a method for producing a fragmented extracellular matrix component comprises a neutralization step, a solvent removal step, a fragmentation step, a replacement step, and a drying step, wherein the drying step is obtained by the replacement step.
- the method may be a step of removing a liquid component from the obtained liquid by a freeze-drying treatment.
- the dried fragmented extracellular matrix component obtained by the method further comprising the replacement step can be redispersed more rapidly. For example, in a method that does not include each of the above steps, it may take about 3 to 5 minutes to redisperse by adding a solvent and performing a pipetting operation.
- the dried fragmented extracellular matrix component obtained by the method comprising the neutralization step, the solvent removal step, the fragmentation step, the replacement step, and the drying step can be dried in a shorter time (e.g., about 1 minute) to allow redispersion.
- the fragmented extracellular matrix component of one embodiment obtained by a method comprising the neutralization step, the solvent removal step, the fragmentation step, the replacement step, and the drying step is more rapidly Possible reasons for redistribution are as follows. Since conventional fragmented extracellular matrix components are highly hydrophilic even after they are defibrated once, the fragmented extracellular matrix components become entangled again in the freeze-drying stage. On the other hand, the fragmented extracellular matrix components according to the above embodiment have a high degree of hydrophobicity, and re-entanglement of the fragmented extracellular matrix components with each other via water is suppressed. Freeze-drying is possible. As a result, the fragmented extracellular matrix components are thought to be able to redisperse more rapidly.
- fragmented extracellular matrix component acquires hydrophobicity in the process of substituting the fragmented extracellular matrix component with water and then freeze-drying.
- the reason why the fragmented extracellular matrix component can be redispersed more rapidly is not limited to the above.
- the dried fragmented extracellular matrix component according to the present embodiment can typically be obtained by the method for producing the fragmented extracellular matrix component according to the present embodiment described above.
- the dried fragmented extracellular matrix component according to the present embodiment may be a laminate of fibrous extracellular matrix components having an average diameter of 0.08 ⁇ m or more and 2.0 ⁇ m or less. By having such a structure, it becomes excellent in redispersibility.
- the average diameter is preferably 0.1 ⁇ m or more and 1.5 ⁇ m or less, more preferably 0.3 ⁇ m or more and 1.0 ⁇ m or less, and even more preferably 0.5 ⁇ m or more and 0.7 ⁇ m or less.
- the dried fragmented extracellular matrix component according to the present embodiment is obtained by preparing a section sample and observing a rectangular area of the section sample with a long side of 1820 ⁇ m and a short side of 1365 ⁇ m with a microscope.
- the area of the region where the outer matrix component exists may be 40% or more and 100% or less of the area of the observed image. By having such a structure, it becomes excellent in redispersibility.
- the above ratio may be 40% or more and 95% or less, 40% or more and 90% or less, 40% or more and 85% or less, 40% or more and 80% or less, or 40% or more and 75% or less, 45% or more and 100% or less, 45% to 95%, 45% to 90%, 45% to 85%, 45% to 80%, or 45% to 75%, 50% to 100%, 50% or more 95% or less, 50% or more and 90% or less, 50% or more and 85% or less, 50% or more and 80% or less, or 50% or more and 75% or less, 55% or more and 100% or less, 55% or more and 95% or less , 55% to 90%, 55% to 85%, 55% to 80%, or 55% to 75%, 60% to 100%, 60% to 95%, 60% 60% to 85%, 60% to 80%, or 60% to 75%, 65% to 100%, 65% to 95%, 65% to 90% 65% or more and 85% or less, 65% or more and 80% or less, or 65% or more and 75% or less.
- the fragmented extracellular matrix component according to this embodiment has a peak within a wavelength range of 400 nm or more and 550 nm or less in fluorescence intensity measurement using 1,8-anilinonaphthalenesulfonic acid (ANS).
- the fragmented extracellular matrix component can be suitably produced by the method for producing a fragmented extracellular matrix component according to the present embodiment described above.
- the fragmented extracellular matrix component according to this embodiment may have a peak in the wavelength range of 420 nm or more and 500 nm or less or 425 nm or more and 475 nm in fluorescence intensity measurement using ANS.
- ANS is a hydrophobic probe.
- fluorescence intensity measurement using ANS shows a peak within the wavelength range of 400 nm or more and 550 nm or less, it can be determined that the fragmented extracellular matrix component has hydrophobicity.
- the fragmented extracellular matrix component to be measured is added to phosphate-buffered saline (1 ⁇ PBS) at a concentration of 5 mg/mL.
- the solution containing the fragmented extracellular matrix components is stored in a refrigerator for 4 days to dissolve the fragmented extracellular matrix. Let this be a fragmented extracellular matrix solution.
- Magnesium(II) 8-anilino-1-naphthalenesulfonate (ANS-8-Mg) is dissolved in phosphate buffered saline (1 ⁇ PBS) to a concentration of 20 ⁇ M. This is called an ANS-Mg aqueous solution.
- Fluorescence intensity measurement is performed under the conditions shown below.
- Measuring instrument spectrophotometer (for example, NanoDrop TM 3300 fluorophotometer (manufactured by ThermoFischer Scientific)) Excitation wavelength: 380 nm Measurement wavelength: 400-750nm
- the fragmented extracellular matrix component according to the present embodiment has a peak in the wavelength range of 400 nm or more and 550 nm or less in fluorescence intensity measurement using 1,8-anilinonaphthalenesulfonic acid (ANS), so it can be rapidly reproduced. Dispersion is possible.
- the fluorescence intensity of the fragmented extracellular matrix component measured using ANS may be twice or more the fluorescence intensity of the extracellular matrix component before fragmentation measured using ANS.
- the fluorescence intensity of the extracellular matrix component before fragmentation measured using ANS is the extracellular matrix component before fragmentation (raw material of the fragmented extracellular matrix) instead of the fragmented extracellular matrix component. Fluorescence intensity is measured in the same manner, except that the extracellular matrix component with
- the method for producing a cell structure according to the present embodiment includes a step of mixing the fragmented extracellular matrix components obtained by the method for producing a fragmented extracellular matrix according to the present embodiment with cells (mixing step); and a step of incubating the mixture obtained in the step of performing (incubating step).
- cell structure refers to an aggregate of cells (massive cell population) in which cells are three-dimensionally arranged via an extracellular matrix component, and is artificially produced by cell culture. means the aggregate that is created.
- the shape of the cell structure is not particularly limited. , a substantially rectangular parallelepiped shape, and the like.
- the cell structure may be aggregated in a state of adhering to the support, or may be aggregated in a state of not adhering to the support.
- the mixing step is a step of mixing the fragmented extracellular matrix component obtained by the method for producing a fragmented extracellular matrix according to the present embodiment with cells.
- Cells are not particularly limited, but may be, for example, cells derived from mammals such as humans, monkeys, dogs, cats, rabbits, pigs, cows, mice, and rats.
- the site of cell origin is not particularly limited, and may be somatic cells derived from bones, muscles, internal organs, nerves, brains, bones, skin, blood, or the like, or germ cells.
- the cells may be stem cells, or cultured cells such as primary cultured cells, subcultured cells and cell line cells.
- the mixing step includes a method of mixing an aqueous medium containing fragmented extracellular matrix components and an aqueous medium containing cells, a method of adding and mixing cells to an aqueous medium containing fragmented extracellular matrix components, A method of adding an aqueous medium containing fragmented extracellular matrix components to a culture medium containing cells and mixing them, and a method of adding fragmented extracellular matrix components and cells to a previously prepared aqueous medium and mixing them. Examples include, but are not limited to.
- the concentration of the fragmented extracellular matrix component in the mixing step can be appropriately determined according to the shape and thickness of the target cell structure, the size of the incubator, and the like.
- the concentration of the fragmented extracellular matrix component in the aqueous medium in the mixing step may be 0.1-90% by mass, or 1-30% by mass.
- the amount of the fragmented extracellular matrix component in the mixing step is, for example, 0.1 to 100 mg, 0.5 to 50 mg, 0.8 to 25 mg, 1.0 to 1.0 mg for 1.0 ⁇ 10 6 cells. 10 mg, 1.0-5.0 mg, 1.0-2.0 mg, or 1.0-1.8 mg, 0.7 mg or more, 1.1 mg or more, 1.2 mg or more, 1.3 mg or more Or it may be 1.4 mg or more, and may be 7.0 mg or less, 3.0 mg or less, 2.3 mg or less, 1.8 mg or less, 1.7 mg or less, 1.6 mg or less, or 1.5 mg or less.
- the mass ratio between the fragmented extracellular matrix components and the cells is preferably 1/1 to 1000/1, more preferably 9/1 to 900/1. is more preferable, and 10/1 to 500/1 is even more preferable.
- the incubation step is a step of incubating the mixture obtained in the mixing step.
- the incubating step can also be regarded as a step of culturing the cells in the presence of the fragmented extracellular matrix component.
- the method of culturing cells in the presence of fragmented extracellular matrix components is not particularly limited, and a suitable culture method can be used according to the type of cells to be cultured.
- the culture temperature may be 20°C to 40°C, or 30°C to 37°C.
- the pH of the medium may be 6-8, or 7.2-7.4.
- the culture time may be 1 day to 2 weeks, or 1 week to 2 weeks.
- the incubator (support) used in the incubation step is not particularly limited, and may be, for example, a well insert, a low-adhesion plate, or a plate having a U-shaped or V-shaped bottom surface.
- the cells may be cultured while adhered to the support, the cells may be cultured without adhering to the support, or the cells may be separated from the support during the culture and cultured.
- the base has a U-shaped or V-shaped bottom shape that inhibits the adhesion of the cells to the support. It is preferable to use a plate or a low adsorption plate.
- the medium used in the incubation process is not particularly limited, and a suitable medium can be selected according to the type of cells to be cultured.
- the medium include Eagle's MEM medium, DMEM, Modified Eagle medium (MEM), Minimum Essential medium, RPMI, and GlutaMax medium.
- the medium may be a serum-supplemented medium or a serum-free medium.
- the medium may be a mixed medium in which two types of medium are mixed.
- the cell density in the medium in the incubation step can be appropriately determined according to the shape and thickness of the target cell structure, the size of the incubator, and the like.
- the cell density in the medium in the incubation step may be 1-10 8 cells/mL, or 10 3 -10 7 cells/mL.
- the cell density in the medium in the incubation step may be the same as the cell density in the aqueous medium in the mixing step.
- ⁇ Test Example 1> Production of Fragmented Collagen] 10 ⁇ PBS (manufactured by Nacalai Tesque Co., Ltd.) and 0.05N NaOH aqueous solution were mixed in equal amounts to prepare a neutralization solution. On ice, 4.25 mL of the neutralizing solution is added at once to 17 mL of the collagen solution (pig skin-derived collagen I solution, manufactured by Nippi Co., Ltd., PSC-1-200-100), and pipetted quickly using a pipette. This neutralized the collagen solution. The pH of the collagen solution after neutralization was 7. The neutralized collagen solution was incubated at 37° C. for 2 hours to gel.
- the collagen solution pig skin-derived collagen I solution, manufactured by Nippi Co., Ltd., PSC-1-200-100
- the solvent was removed by freeze-drying to obtain a dry collagen solid (mass containing collagen). All the resulting dry solids were transferred to a 15 mL centrifuge tube, and 10 mL of absolute ethanol was added to disperse them, then using a homogenizer (manufactured by AS ONE, VH-10), homogenization was performed at 30,000 rpm for 6 minutes to obtain collagen. was fragmented (fibrillated). Subsequently, the fragmented collagen was sedimented by centrifugation (10,000 rpm, 3 minutes), and the supernatant ethanol (liquid component) was removed. The precipitated fragmented collagen was dried at room temperature for 3 days, or dried under reduced pressure with a vacuum pump for 2 hours to further remove ethanol (liquid component) to obtain fragmented collagen (fibrillated collagen).
- FIG. 1 is an optical micrograph of fragmented collagen resuspended in ultrapure water.
- FIG. 1(A) shows the fragmented collagen obtained in Production Example 1.
- FIG. 1(B) shows the fragmented collagen obtained in Comparative Production Example 1.
- FIG. The fragmented collagen obtained by the production method according to the present invention (Production Example 1) could be redispersed by pipetting (see FIG. 1(A)).
- the fragmented collagen obtained by the conventional production method (Comparative Production Example 1) could not be redispersed by pipetting, and it was confirmed that aggregates of collagen fibers remained (see FIG. 1(B)). .
- a part of the dried body was scraped off with a cutter, and 50 mM acetic acid was added so that the concentration of the dried body was 1 mg/mL and dissolved overnight at 4°C.
- the resulting solution was diluted 200-fold with 50 mM acetic acid to obtain a solution with a dry matter concentration of 50 ⁇ g/mL.
- the resulting solution was transferred to a quartz cuvette (optical path length 1 mm), and the CD spectrum (wavelength range: 200 to 250 nm) was measured using a circular dichroism spectrometer (manufactured by JASCO Corporation, J-725). bottom.
- FIG. 2 is the CD spectrum of the fragmented collagen obtained in Production Example 1.
- FIG. 2 also shows the CD spectrum of the collagen itself (Native collagen) and the CD spectrum of the collagen freeze-dried after gelation in Production Example 1 (freeze-dried collagen after gelation).
- a peak derived from the triple helical structure unique to collagen is observed in the 220-225 nm region.
- the fragmented collagen obtained in Production Example 1 has a lower peak height than the peaks of the native collagen and the freeze-dried collagen after gelation, which are standard products, but is derived from the triple helical structure peculiar to collagen. A peak was observed. That is, it was revealed that the fragmented collagen obtained in Production Example 1 retained the triple helical structure peculiar to collagen and was not denatured.
- Fig. 3 is a photograph of fragmented collagen stained with hematoxylin and eosin (HE).
- 3(A) and (C) are photographs of the fragmented collagen obtained in Comparative Production Example 1 taken at magnifications of 10 and 40, respectively.
- 3(B) and (D) are photographs of the fragmented collagen obtained in Production Example 1 taken at magnifications of 10 and 40, respectively. While the fragmented collagen obtained in Comparative Production Example 1 forms a ribbon-like network structure (FIGS. 3A and 3C), the fragmented collagen obtained in Production Example 1 has interfiber It had a structure in which the voids were small and fine filamentous fibers were twisted together (FIGS. 3(B) and (D)).
- FIG. 3(A) Photo taken at 10x magnification of the section sample of Comparative Production Example 1.
- the area of the observation image is 1820 ⁇ m (long side) ⁇ 1365 ⁇ m (short side).
- FIG. 3(B) A photograph of the section sample of Production Example 1 taken at a magnification of 10 times.
- the area of the observation image is 1820 ⁇ m (long side) ⁇ 1365 ⁇ m (short side).
- the cell As a result of calculating the area ratio (%) of the region where the outer matrix component is present, it is 39.0 ⁇ 0.5% in FIG. In Example 1), it was 72.3 ⁇ 3.5%.
- the structures of the fragmented collagen (dry body) obtained in Production Example 1 and the fragmented collagen (dry body) obtained in Comparative Production Example 1 were further imaged and observed with a scanning electron microscope (SEM). evaluated.
- SEM scanning electron microscope
- a portion of the dried body was thinly scraped off with a scalpel and attached to a stage for an electron microscope using a carbon tape.
- an osmium coater manufactured by Vacuum Device Co., Ltd., HPC-1SW
- Plasma irradiation was repeated three times.
- the resulting sample was imaged at 5.0 V and 10 ⁇ A using a scanning electron microscope (manufactured by JEOL Ltd., JSM-6701R).
- Fig. 4 is a photograph of fragmented collagen taken with a scanning electron microscope.
- 4(A) and (B) are photographs of the fragmented collagen obtained in Comparative Production Example 1 taken at magnifications of 2000 and 3300, respectively.
- 4(C) and (D) are photographs of the fragmented collagen obtained in Production Example 1 taken at magnifications of 2000 and 3300, respectively.
- the fragmented collagen obtained in Comparative Production Example 1 had a structure in which collagen fibers were laminated in a belt shape (FIGS. 4(A) and (B)).
- the fragmented collagen obtained in Production Example 1 it was confirmed that fine fibers overlapped.
- the average fiber diameter calculated from the captured images was 10.6 ⁇ m for the fragmented collagen obtained in Comparative Production Example 1 and 0.6 ⁇ m for the fragmented collagen obtained in Production Example 1.
- Table 1 summarizes the yields of the fragmented collagen obtained in Production Example 1, Production Examples 2-1 to 2-3, and Comparative Production Example 1.
- the yield referred to here is the ratio (%) of the weight of the obtained fragmented collagen (dry body) to the weight of the collagen used for fragmentation.
- FIG. 5 is an optical micrograph of fragmented collagen resuspended in ultrapure water.
- FIG. 5(A) shows the fragmented collagen obtained in Production Example 1.
- FIG. 5(B) shows the fragmented collagen obtained in Production Example 2-3.
- FIG. 5(C) shows the fragmented collagen obtained in Production Example 2-1. Although not shown, similar results were obtained with the fragmented collagen obtained in Production Example 2-2.
- FIG. 6 shows the CD spectrum of the fragmented collagen obtained in Production Example 2-3.
- FIG. 6 also shows the CD spectrum of gelatin (having no triple helix structure) and the CD spectrum of collagen itself (Native collagen). Although not shown, similar results were obtained for the fragmented collagen obtained in Production Examples 2-1 and 2-2.
- FIG. 7 is an optical micrograph of fragmented collagen resuspended in ultrapure water.
- FIG. 7(A) shows the fragmented collagen obtained in Production Example 3-1.
- FIG. 7(B) shows the fragmented collagen obtained in Production Example 3-2.
- FIG. 7(C) shows the fragmented collagen obtained in Production Example 3-3.
- the structure of collagen after neutralization and collagen after neutralization-gelation was evaluated by imaging and observing with a scanning electron microscope (SEM).
- SEM scanning electron microscope
- FIG. 8 is a photograph taken with a scanning electron microscope of collagen after neutralization and after neutralization-gelation.
- FIGS. 8(A) and (C) are photographs of collagen after neutralization and gelation, taken at magnifications of 500 and 2000, respectively.
- FIGS. 8(B) and (D) are photographs of neutralized collagen taken at magnifications of 500 and 2000, respectively. No significant difference was observed in the structures of collagen after neutralization and collagen after neutralization-gelation. It is thought that neutralization of the collagen solution changes the structure of the collagen molecules, thereby exhibiting the effect of the present invention that the redispersibility is excellent.
- NHDF Human normal skin fibroblasts
- HAVEC human umbilical vein endothelial cells
- the inserts were transferred to a 6-well culture plate and mixed with EGM (registered trademark)-2MV Bullet Kit (registered trademark) (CC-3202, manufactured by Lonza Co., Ltd.) and DMEM medium containing 10% serum at a ratio of 1:1. Cultured for 7 days. After culturing, the cells were fixed overnight at room temperature with 4% paraformaldehyde/phosphate buffer, and after embedding in paraffin, sliced specimens were HE-stained and CD31-stained. For the fragmented collagen (dried body) obtained in Comparative Production Example 1, a cell structure was prepared by the same procedure as described above, and HE-stained.
- FIG. 10 is a photograph of a cell structure stained with hematoxylin and eosin (HE) (FIGS. 10 (A) and (C)) or immunostained with CD31 (FIG. 10 (B)).
- 10(A) and (B) are cell structures produced using the fragmented collagen obtained in Production Example 1.
- FIG. 10(C) shows a cell structure produced using the fragmented collagen obtained in Comparative Production Example 1.
- FIG. 10 As shown in FIG. 10, the cell structure produced using the fragmented collagen obtained in Production Example 1 was produced using the fragmented collagen obtained in Comparative Production Example 1, although some collagen aggregation was observed. Almost the same tissue as the cell structure (conventional method) was constructed (FIGS. 10(A) and (C)).
- the cell structure prepared using the fragmented collagen obtained in Production Example 1 showed no noticeable cell death, and CD31 staining revealed that blood vessels with a tubular structure were also constructed. (Fig. 10(B)).
- Production Example 5-1 A neutralizing solution was prepared by mixing equal parts of 10 ⁇ PBS and 0.05N NaOH. To 17 mL of collagen solution on ice, 4.25 mL of neutralizing solution was added all at once and the collagen solution was harmonized by pipetting quickly with a pipette. The neutralized collagen solution was incubated at 37°C for 2 hours to gel. The resulting gel was frozen in liquid nitrogen and then freeze-dried for at least 48 hours to obtain a dry collagen solid (mass containing collagen) subjected to a freeze-drying treatment after gelation.
- Reference example 3 10 ⁇ PBS (manufactured by Nacalai Tesque Co., Ltd.) and 0.05N NaOH aqueous solution were mixed in equal amounts to prepare a neutralization solution.
- the neutralizing solution is added at once to 17 mL of the collagen solution (pig skin-derived collagen I solution, manufactured by Nippi Co., Ltd., PSC-1-200-100), and pipetted quickly using a pipette. This neutralized the collagen solution.
- the pH of the collagen solution after neutralization was 7.
- the neutralized collagen solution was incubated at 37° C. for 2 hours to gel. After freezing the resulting gel in liquid nitrogen, the solvent was removed by freeze-drying to obtain a dry collagen solid (mass containing collagen).
- the cell-containing solution was dispensed into 24-well inserts (Corning/#3470) in prescribed amounts, and the plate was centrifuged at 1,100 xg for 15 minutes.
- the inserts were transferred to a 6-well culture plate and the cells were cultured for 7 days in a 1:1 mixture of EGM TM -2MV BulletKit TM and DMEM with 10% serum.
- the tissue body obtained by the culture was fixed overnight at room temperature with 4% paraformaldehyde/phosphate buffer, and after embedding in paraffin, a sliced specimen was stained with hematoxylin/eosin (HE staining).
- FIG. 12 is a photograph of the fragmented collagen of Production Example 5-4 taken with a phase-contrast microscope. Fragmentation (microfiber formation) of collagen was also confirmed from the phase-contrast micrograph (Fig. 12).
- fragmented collagen In the production of fragmented collagen, after fragmenting collagen in a solution containing ethanol, freeze-drying is performed without replacing the liquid component with ultrapure water to obtain fragmented collagen (Reference Example 3 ), the dried fragmented collagen is hard and requires pipetting for about 5 minutes to redisperse it.In addition, when the ethanol concentration of the solution when fragmenting collagen increases, drying is required to obtain a dried fragment. There was a drawback that the time was very long (about two weeks). On the other hand, the method of obtaining fragmented collagen by fragmenting collagen in a solution containing ethanol, replacing the liquid component with ultrapure water, and then subjecting it to freeze-drying does not have such drawbacks.
- FIG. 13 shows measurement results of CD spectra of gelatin, raw material collagen (non-fragmented collagen, Native Collagen), and fragmented collagen of Production Example 5-4.
- FIG. 14 shows measurement results of CD spectra of gelatin, raw material collagen (Native Collagen), and fragmented collagen of Production Example and Comparative Production Example.
- FIG. 15 shows the fragmented collagen obtained by the method of Production Example 5-1 (Example) or the fragmented collagen obtained by the method of Reference Example 3 (Reference Example), and stained with hematoxylin and eosin (HE). , or CD31 immunostained cell structures.
- the fragmented collagen of Production Example was organized without dissolving even when replaced with a medium in which cells were suspended.
- the fragmented collagen of Production Example 5-5 which was fibrillated using a homogenizer in ethanol, has the property that it does not dissolve easily even if the liquid component is replaced with ultrapure water after fragmentation. Further defibration by sound waves could be performed.
- FIG. 16 shows a micrograph of the fragmented collagen of Production Example 5-5. As shown in FIG. 16, the fibers are disentangled before being ultrasonically crushed, but the individual fibers themselves are entangled. It was confirmed that the fibers after ultrasonic crushing were dispersed one by one in the liquid, although there was not much difference in length between them.
- FIG. 17 is a photograph of a cell structure produced using the fragmented collagen of Production Example 5-5 and stained with hematoxylin and eosin (HE) or immunostained with CD31. Before sonication, collagen clumps can be seen (circles) and the distribution of cells is uneven, but after sonication, no collagen clumps can be seen, and the cells are evenly distributed. state was shown.
- HE hematoxylin and eosin
- Fig. 18 shows photographs of collagen defibrated using various polar organic solvents. Fiber formation was possible even when a polar organic solvent other than ethanol was used.
- ANS-8 Mg magnesium (II) 8-anilino-1-naphthalenesulfonate) (Tokyo Chemical Industry Co., Ltd., product code: A5353) was dissolved in 1 ⁇ PBS to 20 ⁇ M, and the ANS-Mg aqueous solution was prepared. prepared. 200 ⁇ L of the ANS-Mg aqueous solution was added to 500 ⁇ L of the collagen solution, and the mixture was allowed to react at room temperature (25° C.) with the light shielded for one hour. Using the resulting reaction solution, the spectrum of the sample was measured with a spectrophotometer (Nanodrop 3300/ThermoFischer scientific) at a wavelength of 380 nm.
- FIG. 19 shows the measurement results of the spectrum.
- “New Method CMF” indicates the measurement results when using the fragmented collagen of Production Example 5-4
- “Normal CMF” indicates the measurement results when using the fragmented collagen of Reference Example 3.
- “Native collagen” indicates the measurement results when a lyophilized solution of collagen was used.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
[1]断片化細胞外マトリックス成分の製造方法であって、
細胞外マトリックス成分が溶解した溶液を中和する工程と、
上記中和する工程の後、凍結乾燥処理により溶媒を除去して、細胞外マトリックス成分を含む塊を得る工程と、
上記塊を極性有機溶媒を含む溶液中に分散させ、当該溶液中で細胞外マトリックス成分を断片化し、断片化細胞外マトリックス成分を含む液体を得る工程と、
上記断片化細胞外マトリックス成分を含む液体から液体成分を除去する工程と、を備える、製造方法。
[2]上記液体を得る工程の後、かつ上記液体成分を除去する工程の前に、上記液体を得る工程で得られた上記液体中の液体成分を水に置換する工程を更に備え、上記液体成分を除去する工程において、前記断片化細胞外マトリックス成分を含む液体から凍結乾燥処理により液体成分を除去する、[1]に記載の製造方法。
[3]上記水に置換する工程の後、かつ上記液体成分を除去する工程の前に、上記断片化細胞外マトリックス成分を含む液体に超音波破砕処理を行う工程を更に備える、[2]に記載の製造方法
[4]上記中和する工程の後、かつ上記塊を得る工程の前に、中和した上記溶液をゲル化する工程を更に備える、[1]~[3]のいずれかに記載の製造方法。
[5]上記塊が多孔質体である、[4]に記載の製造方法。
[6]上記断片化することが、細胞外マトリックス成分を解繊することを含む、[1]~[5]のいずれかに記載の製造方法。
[7]上記極性有機溶媒を含む溶液中の上記極性溶媒の濃度が、20v/v%以上100v/v%以下である、[1]~[6]のいずれかに記載の製造方法。
[8]上記極性有機溶媒がエタノールを含む、[1]~[7]のいずれかに記載の製造方法。
[9]上記液体成分を除去する工程で得られた固形物を水性媒体に分散させる工程を更に備える、[1]~[8]のいずれかに記載の製造方法。
[10]上記細胞外マトリックス成分がコラーゲンである、[1]~[9]のいずれかに記載の製造方法。
[11]上記断片化細胞外マトリックス成分がコラーゲンに特有の三重らせん構造を有する、[10]に記載の製造方法。
[12][1]~[11]のいずれかに記載の製造方法により得られた断片化細胞外マトリックス成分と、細胞を混合する工程と、
上記混合する工程で得られた混合物をインキュベートする工程と、
を含む、細胞構造体の製造方法。
[13]平均径が0.08μm以上2.0μm以下である繊維状の細胞外マトリックス成分が積層されている、断片化細胞外マトリックス成分の乾燥体。
[14]切片標本を作製し、上記切片標本の長辺1820μmかつ短辺1365μmの長方形領域を顕微鏡によって観察して取得される観察画像において、細胞外マトリックス成分が存在する領域の面積が、上記観察画像の面積に対して40%以上100%以下である、[13]に記載の断片化細胞外マトリックス成分の乾燥体。
[15]上記断片化細胞外マトリックス成分が断片化コラーゲンである、[13]又は[14]に記載の断片化細胞外マトリックス成分の乾燥体。
[16]
1,8-アニリノナフタレンスルホン酸(ANS)を使用した蛍光強度測定で、波長400nm以上550nm以下の範囲内にピークを有する、断片化細胞外マトリックス成分。
本実施形態に係る断片化細胞外マトリックス成分の製造方法は、細胞外マトリックス成分が溶解した溶液を中和する工程(中和工程)と、中和する工程の後、凍結乾燥処理により溶媒を除去して、細胞外マトリックス成分を含む塊を得る工程(溶媒除去工程)と、塊を極性有機溶媒を含む溶液中に分散させ、当該溶液中で細胞外マトリックス成分を断片化し、断片化細胞外マトリックス成分を含む液体を得る工程(断片化工程)と、断片化細胞外マトリックス成分を含む液体から液体成分を除去する工程(乾燥工程)と、を備える。
中和工程は、細胞外マトリックス成分が溶解した溶液を中和する工程である。中和することにより、細胞外マトリックスの構造が変化するため、後の工程と併せて実施することで、乾燥状態で保存しても再分散性に優れる断片化細胞外マトリックス成分を得ることができるようになる。
ゲル化工程は、中和工程の後、かつ溶媒除去工程の前に、中和した溶液をゲル化する工程である。ゲル化工程は、必要に応じて実施すればよい。
溶媒除去工程は、中和工程の後(ゲル化工程を含む場合は、ゲル化工程の後)、凍結乾燥処理により溶媒を除去して、細胞外マトリックス成分を含む塊を得る工程である。
断片化工程は、溶媒除去工程で得られた塊を極性有機溶媒を含む溶液中に分散させ、当該溶液中で細胞外マトリックス成分を断片化し、断片化細胞外マトリックス成分を含む液体を得る工程である。
置換工程は、断片化工程の後、かつ乾燥工程の前に、断片化工程で得られた液体中の液体成分を水に置換する工程である。
超音波破砕工程は、断片化工程で得られた液体に超音波破砕処理を行う工程である。超音波破砕工程は、必要に応じて実施すればよい。超音波破砕工程を経ることで、より均一に分散され、組織化に用いる際により凝集が起こりにくい断片化細胞外マトリックス成分を得ることができる。超音波破砕処理には、冷却しながら断片化細胞外マトリックス成分を破砕できるため、断片化細胞外マトリックス成分が熱変性する可能性が低い、及び、大規模な設備が必要ないという利点がある。
乾燥工程は、断片化工程で得られた断片化細胞外マトリックス成分を含む液体から液体成分を除去する工程である。
洗浄工程は、乾燥工程で得られた固形物を水性媒体に分散させる工程である。洗浄工程は、必要に応じて実施すればよい。洗浄工程により、断片化細胞外マトリックス成分を含む固形物から不要な成分(例えば、塩等)が除去され、より純度の高い断片化細胞外マトリクス成分を得ることができる。
本実施形態に係る断片化細胞外マトリックス成分の乾燥体は、典型的には、上述した本実施形態に係る断片化細胞外マトリックス成分の製造方法により得ることができるものである。
測定機器:分光光度計(例えば、NanoDropTM 3300 蛍光光度計(ThermoFischer scientific社製))
励起波長:380nm
測定波長:400~750nm
本実施形態に係る細胞構造体の製造方法は、本実施形態に係る断片化細胞外マトリックスの製造方法により得られた断片化細胞外マトリックス成分と、細胞を混合する工程(混合工程)と、混合する工程で得られた混合物をインキュベートする工程(インキュベート工程)と、を含む。
混合工程は、本実施形態に係る断片化細胞外マトリックスの製造方法により得られた断片化細胞外マトリックス成分と、細胞を混合する工程である。
インキュベート工程は、混合工程で得られた混合物をインキュベートする工程である。インキュベート工程は、断片化細胞外マトリックス成分の存在下で細胞を培養する工程と捉えることもできる。
〔製造例1:断片化コラーゲンの製造〕
10×PBS(ナカライテスク株式会社製)と0.05N NaOH水溶液を等量ずつ混合し、中和用溶液を調製した。氷上で、17mLのコラーゲン溶液(ブタ皮膚由来コラーゲンI溶液,株式会社ニッピ製,PSC-1-200-100)に4.25mLの中和用溶液を一気に添加し、ピペットを用いて素早くピペッティングすることでコラーゲン溶液を中和した。中和後のコラーゲン溶液のpHは7であった。中和後のコラーゲン溶液を37℃で2時間インキュベートし、ゲル化した。得られたゲルを液体窒素で凍結させた後、凍結乾燥により溶媒を除去して、コラーゲンの乾燥固体(コラーゲンを含む塊)を得た。得られた乾燥固体全てを15mL遠沈管に移し、10mLの無水エタノールを加えて分散させた後、ホモジナイザー(アズワン社製,VH-10)を使用し、30,000rpmで6分間ホモジナイズして、コラーゲンを断片化(解繊)した。次いで、遠心分離(10,000rpm,3分間)して断片化コラーゲンを沈降させ、上澄みのエタノール(液体成分)を除去した。沈降した断片化コラーゲンを室温にて3日間乾燥、又は真空ポンプで2時間減圧乾燥させて、エタノール(液体成分)を更に除去し、断片化コラーゲン(解繊コラーゲン)を得た。
17mLのコラーゲン溶液(ブタ皮膚由来コラーゲンI溶液,株式会社ニッピ製,PSC-1-200-100)を凍結乾燥し、コラーゲンの乾燥体を得た。得られた乾燥体50mgに10×PBSを加えて分散させた後、ホモジナイザー(アズワン社製,VH-10)を使用し、30,000rpmで6分間ホモジナイズして、コラーゲンを断片化(解繊)した。次いで、遠心分離(10,000rpm,3分間)して断片化コラーゲンを沈降させ、上澄み(液体成分)を除去した。沈降した断片化コラーゲンを凍結乾燥し、断片化コラーゲン(解繊コラーゲン)を得た。
製造例1で得た断片化コラーゲン(乾燥体)、及び比較製造例1で得た断片化コラーゲン(乾燥体)それぞれの再分散性を評価した。まず、乾燥体それぞれに5mLの1×PBS(ナカライテスク株式会社製,1424924)(37℃)を加え、ピペッティングにて塊を崩しながら溶液中に再分散させた。次いで、遠心分離(10,000rpm,3分間)してPBSを除去した後、超純水5mLに再懸濁させた。
製造例1で得た断片化コラーゲン(乾燥体)のCDスペクトルの測定を実施し、三次元構造を評価した。
製造例1で得た断片化コラーゲン(乾燥体)、及び比較製造例1で得た断片化コラーゲン(乾燥体)の構造を、ヘマトキシリン・エオジン(HE)染色により評価した。HE染色は、それぞれの乾燥体から作製した切片標本に対して常法に従って実施した。
コラーゲンを断片化する際の溶液を無水エタノールから20v/v%エタノール水溶液(エタノール:水=20:80)(製造例2-1)、50v/v%エタノール水溶液(エタノール:水=50:50)(製造例2-2)、又は70v/v%エタノール水溶液(エタノール:水=70:30)(製造例2-3)に代えたこと以外は、製造例1と同様の手順で断片化コラーゲンを製造した。
10×PBS(ナカライテスク株式会社製)と0.05N NaOH水溶液を等量ずつ混合し、中和用溶液を調製した。氷上で、17mLのコラーゲン溶液(ブタ皮膚由来コラーゲンI溶液,株式会社ニッピ製,PSC-1-200-100)に4.25mLの中和用溶液を一気に添加し、ピペットを用いて素早くピペッティングすることでコラーゲン溶液を中和した。中和後のコラーゲン溶液のpHは7であった。中和後のコラーゲン溶液を37℃で2時間インキュベートし、ゲル化した。得られたゲルを液体窒素で凍結させた後、凍結乾燥により溶媒を除去して、コラーゲンの乾燥固体(コラーゲンを含む塊)を得た。得られた乾燥固体全てを15mL遠沈管に移し、15mLのアセトニトリル(製造例3-1)、アセトン(製造例3-2)、又はジエチルエーテル(製造例3-3)を加えて分散させた後、ホモジナイザー(アズワン社製,VH-10)を使用し、30,000rpmで6分間ホモジナイズして、コラーゲンを断片化(解繊)した。次いで、遠心分離(10,000rpm,3分間)して断片化コラーゲンを沈降させ、上澄み(液体成分)を除去した。沈降した断片化コラーゲンを室温にて風乾し、製造例3-1~3-3の断片化コラーゲン(解繊コラーゲン)を得た。
10×PBS(ナカライテスク株式会社製)と0.05N NaOH水溶液を等量ずつ混合し、中和用溶液を調製した。氷上で、17mLのコラーゲン溶液(ブタ皮膚由来コラーゲンI溶液,株式会社ニッピ製,PSC-1-200-100)に4.25mLの中和用溶液を一気に添加し、ピペットを用いて素早くピペッティングすることでコラーゲン溶液を中和した。中和後のコラーゲン溶液のpHは7であった。これを凍結乾燥して中和後のコラーゲンとした。また、中和後のコラーゲン溶液を37℃で2時間インキュベートしてゲル化し、このゲルを凍結乾燥して中和-ゲル化後のコラーゲンとした。
10×PBS(ナカライテスク株式会社製)と0.05N NaOH水溶液を等量ずつ混合し、中和用溶液を調製した。氷上で、5mM酢酸に溶解させたコラーゲン溶液500μLに中和用溶液0.7mL、1.25mL又は1.7mLを一気に添加し、ピペットを用いて素早くピペッティングすることで中和した。中和後のコラーゲン溶液のpHは、それぞれ6、7又は8であった。中和後のコラーゲン溶液を37℃で30分間インキュベートしたところ、いずれのコラーゲン溶液もゲル化したことが確認された。図9は、ゲル化したコラーゲン溶液の写真である。
製造例1及び比較製造例1で得た断片化コラーゲンを使用し、細胞構造体の製造を行った。
〔材料〕
コラーゲンとして、ブタ皮膚製コラーゲンI溶液(NIPPI/PSC-1-200-100)を使用した
製造例5-1
10×PBSと0.05N NaOHを等量ずつ混合して、中和用溶液を調製した。氷上で17mLのコラーゲン溶液に、4.25mLの中和用溶液を一気に添加し、ピペットを用いて素早くピペッティングすることでコラーゲン溶液を調和した。中和後のコラーゲン溶液を37°Cにて2時間インキュベートし、ゲル化した。得られたゲルを液体窒素にて凍結させた後、最低48時間凍結乾燥し、ゲル化後に凍結乾燥処理を実施したコラーゲンの乾燥固体(コラーゲンを含む塊)を得た。
コラーゲンを断片化する際の溶液に、20v/v%エタノール水溶液(エタノール:水=20:80)(製造例5-2)、50v/v%エタノール水溶液(エタノール:水=50:50)(製造例5-3)、又は70v/v%エタノール水溶液(エタノール:水=70:30)(製造例5-4)を用いたこと以外は製造例5-1と同様にして、それぞれ製造例5-2、5-3及び5-4の断片化コラーゲンを得た。
コラーゲンを断片化する際の溶液に、水(エタノール:水=0:100)を用いたこと以外は、製造例5-1と同様にして、比較製造例5-1の断片化コラーゲンを得た。
10×PBS(ナカライテスク株式会社製)と0.05N NaOH水溶液を等量ずつ混合し、中和用溶液を調製した。氷上で、17mLのコラーゲン溶液(ブタ皮膚由来コラーゲンI溶液,株式会社ニッピ製,PSC-1-200-100)に4.25mLの中和用溶液を一気に添加し、ピペットを用いて素早くピペッティングすることでコラーゲン溶液を中和した。中和後のコラーゲン溶液のpHは7であった。中和後のコラーゲン溶液を37℃で2時間インキュベートし、ゲル化した。得られたゲルを液体窒素で凍結させた後、凍結乾燥により溶媒を除去して、コラーゲンの乾燥固体(コラーゲンを含む塊)を得た。得られた乾燥固体全てを15mL遠沈管に移し、10mLの70v/v%エタノール水溶液(エタノール:水=70:30)を加えて分散させた後、ホモジナイザー(アズワン社製,VH-10)を使用し、30,000rpmで6分間ホモジナイズして、コラーゲンを断片化(解繊)した。次いで、遠心分離(10,000rpm,3分間)して断片化コラーゲンを沈降させ、上澄みのエタノール(液体成分)を除去した。沈降した断片化コラーゲンを室温にて3日間乾燥、又は真空ポンプで2時間減圧乾燥させて、エタノール(液体成分)を更に除去し、参考例3の断片化コラーゲン(解繊コラーゲン)を得た。
コラーゲンを断片化する際の溶液に、70v/v%エタノール水溶液(エタノール:水=70:30)を用いたこと以外は製造例5-1と同様にして、断片化コラーゲン及び超純水を含む液体を得た。断片化コラーゲンを超純水中に懸濁させた状態で、全自動超音波破砕機(BIORUPTERII/ビーエム機器)を用いて、20秒間の超音波照射と、30秒間の冷却とを99回繰り返し、断片化コラーゲンに対して超音波破砕処理を行った。超音波破砕処理後の断片化コラーゲンを純水に分散させた状態で、凍結乾燥し、乾燥固体として、製造例5-5の断片化コラーゲンを得た。
細胞構造体の構築には、製造例5-4の断片化コラーゲン、参考例3の断片化コラーゲン及び製造例5-5の断片化コラーゲンそれぞれを用いた。
断片化コラーゲンの乾燥固体の一部をそれぞれカッターで削り取り、1mg/mLになるように50mM酢酸を加えて4℃で一晩溶解させ、断片化コラーゲン溶液を調製した。断片化コラーゲン溶液を、コラーゲン濃度が50μg/mLになるように50mM酢酸で200倍に希釈し、測定用溶液を得た。光路長1mmの石英キュベットに、測定用溶液を移し、円二色性分散計(JASCO/J-725)を用いて200nm~250nmでのCDスペクトルを測定した
図11は、コラーゲンを断片化する際の溶液に、70v/v%エタノール水溶液(エタノール:水=70:30)を用いて製造した製造例5-4の断片化コラーゲンの再分散性の評価結果を示す写真である。製造例5-4の断片化コラーゲンは、37℃の超純水で1分ほどピペッティングするとほぼ完全に分散しきる様子が確認された(図11)。図12は、製造例5-4の断片化コラーゲンを位相差顕微鏡で撮像した写真である。位相差顕微鏡写真からもコラーゲンが断片化(マイクロファイバー化)していることが確認された(図12)。
図13は、ゼラチン、原料のコラーゲン(非断片化コラーゲン、Native Collagen)及び製造例5-4の断片化コラーゲンのCDスペクトルの測定結果を示す。
収率(%)=V1/V0×100 (1)
図15は、製造例5-1の方法で得た断片化コラーゲン(実施例)又は参考例3の方法で得た断片化コラーゲン(参考例)を用いて作製され、ヘマトキシリン・エオジン(HE)染色、又はCD31による免疫染色した細胞構造体を示す写真である。製造例の断片化コラーゲンは細胞が懸濁された培地に置き換えても溶解することなく組織化した。
解繊時有機溶媒を使用しない従来法では冷却しながら超音波破砕(超音波解繊)すると、コラ―ゲンが解繊中に溶解してしまうため、超音波破砕によってより微細な断片化コラーゲンを得るためには、熱架橋処理によって溶解を防ぐ必要があった。しかし、熱架橋処理によってコラーゲンが変性する場合があるため、熱架橋処理された断片化コラーゲンを用いて得られる組織は、熱架橋処理を行わずに作製された組織とは大きく異なるという欠点があった。エタノール中でホモジェナイザーを用いて解繊した製造例5-5の断片化コラーゲンは、断片化後に、液体成分を超純水に置換しても容易に溶解しないという性質があるため、そのまま超音波による更なる解繊を行うことができた。
70v/v%エタノール水溶液に代えて、アセトン、アセトニトリル又はジエチルエーテルを用いて、製造例5-6(アセトン)、製造例5-7(アセトニトリル)及び製造例5-8(ジエチルエーテル)の断片化コラーゲンを製造した。70v/v%エタノール水溶液に代えて使用した極性有機溶媒の濃度は、100v/v%であった。
製造例5-4の断片化コラーゲン、参考例3の断片化コラーゲン、及び、凍結乾燥した溶液のコラーゲンを1×PBSに5mg/mLの濃度になるように添加し、4日間冷蔵庫にて溶解させて、各種コラーゲン溶液を用意した。
Claims (16)
- 断片化細胞外マトリックス成分の製造方法であって、
細胞外マトリックス成分が溶解した溶液を中和する工程と、
前記中和する工程の後、凍結乾燥処理により溶媒を除去して、細胞外マトリックス成分を含む塊を得る工程と、
前記塊を極性有機溶媒を含む溶液中に分散させ、当該溶液中で細胞外マトリックス成分を断片化し、断片化細胞外マトリックス成分を含む液体を得る工程と、
前記断片化細胞外マトリックス成分を含む液体から液体成分を除去する工程Bと、を備える、製造方法。 - 前記液体を得る工程の後、かつ前記液体成分を除去する工程の前に、前記液体を得る工程で得られた前記液体中の液体成分を水に置換する工程を更に備え、
前記液体成分を除去する工程において、前記断片化細胞外マトリックス成分を含む液体から凍結乾燥処理により液体成分を除去する、請求項1に記載の製造方法。 - 前記水に置換する工程の後、かつ前記液体成分を除去する工程の前に、前記断片化細胞外マトリックス成分を含む液体に超音波破砕処理を行う工程を更に備える、請求項2に記載の製造方法。
- 前記中和する工程の後、かつ前記塊を得る工程の前に、中和した前記溶液をゲル化する工程を更に備える、請求項1~3のいずれか一項に記載の製造方法。
- 前記塊が多孔質体である、請求項4に記載の製造方法。
- 前記断片化することが、細胞外マトリックス成分を解繊することを含む、請求項1~5のいずれか一項に記載の製造方法。
- 前記極性有機溶媒を含む溶液中の前記極性有機溶媒の濃度が、20v/v%以上100v/v%以下である、請求項1~6のいずれか一項に記載の製造方法。
- 前記極性有機溶媒がエタノールを含む、請求項1~7のいずれか一項に記載の製造方法。
- 前記液体成分を除去する工程で得られた固形物を水性媒体に分散させる工程を更に備える、請求項1~8のいずれか一項に記載の製造方法。
- 前記細胞外マトリックス成分がコラーゲンである、請求項1~9のいずれか一項に記載の製造方法。
- 前記断片化細胞外マトリックス成分がコラーゲンに特有の三重らせん構造を有する、請求項10に記載の製造方法。
- 請求項1~11のいずれか一項に記載の製造方法により得られた断片化細胞外マトリックス成分と、細胞を混合する工程と、
前記混合する工程で得られた混合物をインキュベートする工程と、
を含む、細胞構造体の製造方法。 - 平均径が0.08μm以上2.0μm以下である繊維状の細胞外マトリックス成分が積層されている、断片化細胞外マトリックス成分の乾燥体。
- 切片標本を作製し、前記切片標本の長辺1820μmかつ短辺1365μmの長方形領域を顕微鏡によって観察して取得される観察画像において、細胞外マトリックス成分が存在する領域の面積が、前記観察画像の面積に対して40%以上100%以下である、請求項13に記載の断片化細胞外マトリックス成分の乾燥体。
- 前記断片化細胞外マトリックス成分が断片化コラーゲンである、請求項13又は14に記載の断片化細胞外マトリックス成分の乾燥体。
- 1,8-アニリノナフタレンスルホン酸(ANS)を使用した蛍光強度測定で、波長400nm以上550nm以下の範囲内にピークを有する、断片化細胞外マトリックス成分。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22841955.2A EP4328233A1 (en) | 2021-07-12 | 2022-06-29 | Production method of fragmented extracellular matrix component |
JP2023535230A JPWO2023286611A1 (ja) | 2021-07-12 | 2022-06-29 | |
CN202280043275.6A CN117500825A (zh) | 2021-07-12 | 2022-06-29 | 片段化细胞外基质成分的制造方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021115115 | 2021-07-12 | ||
JP2021-115115 | 2021-07-12 | ||
JP2021-187740 | 2021-11-18 | ||
JP2021187740 | 2021-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023286611A1 true WO2023286611A1 (ja) | 2023-01-19 |
Family
ID=84920063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/026062 WO2023286611A1 (ja) | 2021-07-12 | 2022-06-29 | 断片化細胞外マトリックス成分の製造方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4328233A1 (ja) |
JP (1) | JPWO2023286611A1 (ja) |
WO (1) | WO2023286611A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012015055A1 (ja) * | 2010-07-30 | 2012-02-02 | 株式会社ニッピ | コラーゲン粉末および/またはコラーゲン誘導体粉末およびそれらの製造方法 |
WO2018143286A1 (ja) | 2017-01-31 | 2018-08-09 | 凸版印刷株式会社 | 三次元組織体及びその製造方法、並びに、三次元組織体の形成剤 |
WO2019189786A1 (ja) * | 2018-03-29 | 2019-10-03 | 凸版印刷株式会社 | 細胞培養用シート並びに三次元組織体及びその製造方法 |
WO2019208831A1 (ja) * | 2018-04-27 | 2019-10-31 | 凸版印刷株式会社 | 細胞外マトリックス含有組成物、三次元組織体形成用仮足場材及び三次元組織体形成剤並びに三次元組織体から細胞を回収する方法 |
WO2019208832A1 (ja) * | 2018-04-27 | 2019-10-31 | 凸版印刷株式会社 | 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体、三次元組織体形成剤 |
-
2022
- 2022-06-29 JP JP2023535230A patent/JPWO2023286611A1/ja active Pending
- 2022-06-29 EP EP22841955.2A patent/EP4328233A1/en active Pending
- 2022-06-29 WO PCT/JP2022/026062 patent/WO2023286611A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012015055A1 (ja) * | 2010-07-30 | 2012-02-02 | 株式会社ニッピ | コラーゲン粉末および/またはコラーゲン誘導体粉末およびそれらの製造方法 |
WO2018143286A1 (ja) | 2017-01-31 | 2018-08-09 | 凸版印刷株式会社 | 三次元組織体及びその製造方法、並びに、三次元組織体の形成剤 |
WO2019189786A1 (ja) * | 2018-03-29 | 2019-10-03 | 凸版印刷株式会社 | 細胞培養用シート並びに三次元組織体及びその製造方法 |
WO2019208831A1 (ja) * | 2018-04-27 | 2019-10-31 | 凸版印刷株式会社 | 細胞外マトリックス含有組成物、三次元組織体形成用仮足場材及び三次元組織体形成剤並びに三次元組織体から細胞を回収する方法 |
WO2019208832A1 (ja) * | 2018-04-27 | 2019-10-31 | 凸版印刷株式会社 | 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体、三次元組織体形成剤 |
Non-Patent Citations (1)
Title |
---|
TOHID REZAEI TOPRAGGALEH, MOJTABA REZAZADEH VALOJERDI, LEILA MONTAZERI, HOSSEIN BAHARVAND: "A testis-derived macroporous 3D scaffold as a platform for the generation of mouse testicular organoids", BIOMATERIALS SCIENCE, R S C PUBLICATIONS, GB, vol. 7, no. 4, 26 March 2019 (2019-03-26), GB , pages 1422 - 1436, XP055703552, ISSN: 2047-4830, DOI: 10.1039/C8BM01001C * |
Also Published As
Publication number | Publication date |
---|---|
EP4328233A1 (en) | 2024-02-28 |
JPWO2023286611A1 (ja) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muzzarelli et al. | Biological activity of chitosan: ultrastructural study | |
JP4025897B2 (ja) | コラーゲンの調製 | |
JP6903299B2 (ja) | 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体、三次元組織体形成剤 | |
US20210115377A1 (en) | Extracellular-matrix-containing composition, temporary scaffold for three-dimensional tissue formation, three-dimensional tissue formation agent, and method for recovering cells from three-dimensional tissue | |
WO2020203369A1 (ja) | 細胞構造体及び細胞構造体の製造方法 | |
JP7285767B2 (ja) | 細胞システムおよび細胞を保存するための方法 | |
JP5769143B2 (ja) | 細胞培養用基材 | |
EP2453932A1 (en) | Polymeric collagen biomaterials | |
Pang et al. | Interfacial bonding between mineral platelets in bone and its effect on mechanical properties of bone | |
Do Amaral et al. | In vitro and in vivo response of composites based on chitosan, hydroxyapatite and collagen | |
WO2021177407A1 (ja) | 三次元組織体のヤング率を制御する方法、三次元組織体の製造方法、及び三次元組織体 | |
WO2023286611A1 (ja) | 断片化細胞外マトリックス成分の製造方法 | |
Bashiri et al. | Generation of Haploid Spermatids on Silk Fibroin‐Alginate‐Laminin‐Based Porous 3D Scaffolds | |
Antoshin et al. | Semipermeable barrier-assisted electrophoretic deposition of robust collagen membranes | |
JP2023118084A (ja) | ex vivo腫瘍免疫微小環境モデル、ex vivo腫瘍免疫微小環境モデルにおいて腫瘍特異的な免疫細胞プロファイルを保存する方法およびナノフィブリルセルロースの使用 | |
CN117500825A (zh) | 片段化细胞外基质成分的制造方法 | |
WO2022113540A1 (ja) | 組織体の製造方法、及び脂肪由来幹細胞の分化促進方法 | |
JP6797389B1 (ja) | 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体及びその製造方法 | |
WO2022173058A1 (ja) | 三次元組織体の製造方法及び脂肪由来幹細胞の分化促進方法 | |
Bobrova et al. | Natural silk fiber microcarriers for cell culture | |
WO2022091822A1 (ja) | 細胞構造体の凍結方法 | |
CN117286601B (zh) | 一种可食性骨胶原蛋白纤维自组装制备方法及应用 | |
Mohammadi et al. | Polycaprolactone/Testicular Extracellular Matrix/Graphene Oxide‐Based Electrospun Tubular Scaffolds for Reproductive Medicine: Biomimetic Architecture of Seminiferous Tubules | |
JP2024073646A (ja) | 細胞構造体及び細胞構造体の製造方法 | |
JP2022036357A (ja) | 細胞構造体及び細胞構造体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22841955 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023535230 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022841955 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022841955 Country of ref document: EP Effective date: 20231121 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280043275.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |